Nikolaus de Gregorio

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Isabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata et al. · New England Journal of Medicine · 2019 · 1.9K citations · Full text

Adjuvant Therapy in Lymph Node–Positive Vulvar Cancer: The AGO-CaRE-1 Study

Sven� Mahner, J Jueckstock, Felix Hilpert et al. · JNCI Journal of the National Cancer Institute · 2015 · 226 citations · Full text

Prevalence of <i>BRCA1/2</i> germline mutations in 21 401 families with breast and ovarian cancer

Karin Kast, Kerstin Rhiem, Barbara Wappenschmidt et al. · Journal of Medical Genetics · 2016 · 217 citations

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

Andreas du Bois, Gunnar B. Kristensen, Isabelle Ray‐Coquard et al. · The Lancet Oncology · 2015 · 207 citations · Full text

Placebo-controlled Phase 3, Medicine, Metronomic Therapy +9

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Jacobus Pfisterer, Catherine Shannon, Klaus Baumann et al. · The Lancet Oncology · 2020 · 157 citations

Medicine, Metronomic Therapy, Gynecology +8